{"id":746,"date":"2020-06-15T15:16:34","date_gmt":"2020-06-15T14:16:34","guid":{"rendered":"https:\/\/blog.iese.edu\/entrepreneurship\/?p=746"},"modified":"2021-07-27T12:31:08","modified_gmt":"2021-07-27T11:31:08","slug":"iese-finaves-invests-neurotech-inbrain","status":"publish","type":"post","link":"https:\/\/blog.iese.edu\/entrepreneurship\/2020\/06\/15\/iese-finaves-invests-neurotech-inbrain\/","title":{"rendered":"IESE\u2019s Finaves Invests in Neurotech Startup InBrain"},"content":{"rendered":"

\"\"<\/a><\/p>\n

Finaves<\/strong> V<\/a>, IESE\u2019s venture capital fund, is part of a group of investors providing \u20ac900,000 in financing for InBrain Neuroelectronics<\/a><\/strong>, a startup that is developing graphene-based technologies to treat neurological disorders such as epilepsy and Parkinson\u2019s with unprecedented precision.<\/p>\n

Finaves contributed \u20ac150,000 to the round, which was led by Sabadell-Asabys<\/strong> and Alta Life Sciences<\/strong>, two Barcelona-based funds that specialize in healthcare. Other partners in the round were the Institut Catal\u00e1 de Finances (ICF)<\/strong>, the research center Institut Catal\u00e1 de Nanoci\u00e9ncia i Nanotecnologia (ICN2)<\/strong> and venture capital firm Ysios Capital<\/strong>.<\/p>\n

InBrain is founded and managed by a team of leading experts in the fields of neuroelectronics and business management. CEO and co-founder Carolina Aguilar<\/strong> worked for more than a decade as business director of medical technology and services company Medtronic, responsible for the global commercialization of the company\u2019s neurological business, with a particular focus on deep brain stimulation (DBS).<\/p>\n

Jose Garrido, founder and chief scientific officer<\/strong>, is a renowned expert in the field of graphene technology, and Mario Capizzani<\/a>, co-founder and chief commercial officer, is a marketing professor at IESE<\/strong>.<\/p>\n

InBrain, a spin-off of ICN2, is developing neuroelectronic therapies that use graphene interfaces to stimulate areas of the brain in better and more targeted ways<\/strong>. The \u200b\u200bthinnest known material, graphene is also incredibly strong, is an excellent conductor and has interesting light absorption abilities. Due to its superior material characteristics, graphene-based implants can be designed smaller than traditional metal-based implants, which allows for a more precise stimulation of diseased brain areas and fewer side effects.<\/p>\n

Today up to 50% of DBS candidates refuse therapy do to its invasiveness and more than 35% drug resistant brain disorder patients remain without treatment. InBrain\u2019s technology will help these patients by offering a less invasive more efficient treatment of their disease.<\/p>\n","protected":false},"excerpt":{"rendered":"

Finaves V, IESE\u2019s venture capital fund, is part of a group of investors providing \u20ac900,000 in financing for InBrain Neuroelectronics, a startup that is developing graphene-based technologies to treat neurological disorders such as epilepsy and Parkinson\u2019s with unprecedented precision. Finaves contributed \u20ac150,000 to the round, which was led by Sabadell-Asabys and Alta Life Sciences, two […]<\/p>\n","protected":false},"author":2207,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[157,159,64812],"tags":[110910,918,80159],"coauthors":[111818],"class_list":["post-746","post","type-post","status-publish","format-standard","hentry","category-entrepreneurship","category-investors","category-startups","tag-finaves","tag-investment","tag-startup"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t